S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CTNM · Contineum Therapeutics, Inc. Class A
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Contineum Therapeutics Inc (CTNM)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$8.33
-0.14
(-1.65%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$8.33
$8.26
$8.76
52-WEEK RANGE
$8.33
$6.72
$17.79
What's happening
- CTNM is down 1.65% today, trading at $8.33. — Live quote
- Volume today (60,695) is well below its 3-month average of 694,570. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.40 actual vs. $-0.46 estimated (+13.2%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 6
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (14 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CTNM
-25.98%
vs S&P 500
-38.76%
1-YEAR RETURN
CTNM
-23.72%
vs S&P 500
-38.28%
6-MONTH RETURN
CTNM
-36.39%
3-MONTH RETURN
CTNM
-39.14%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.40
Est. $-0.46
BEAT +13.2%
2026-04-26 (Q1 2026)
$-0.39
Est. $-0.54
BEAT +28.1%
2026-01-26 (Q4 2025)
$-0.49
Est. $-0.41
MISS -18.4%
2025-10-26 (Q3 2025)
$-0.45
Est. $-0.49
BEAT +8.8%
Valuation Measures & Ratios
Enterprise Value4$303.6M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)6.37
Price / Book72.56
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-24.73%
Return on Assets (ROA9)-23.51%
Avg Volume (3M)694,570
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $620.6M | $483.7M | — | $102.3M | $180.5M |
| P/E | -10.62 | -8.16 | — | -1.99 | -4.13 |
| Price/Book | 2.59 | 1.93 | — | 0.60 | 0.98 |
| EV/EBITDA | -9.07 | -6.86 | — | — | — |
| ROE | -24.39% | -23.71% | — | -29.94% | -23.64% |
| ROA | -23.34% | -22.68% | — | -28.05% | -22.03% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short3,067,588
Change from Prior Settlement+25.53%
% of Float—
Days to Cover (Short Ratio)3.62
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -23.7%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CTNM
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | — |
| Operating income | -$17.4M | -$16.9M | -$14.9M | -$17.9M | -$18.1M | -$13.0M | -$10.9M | -$9.9M |
| Net income | -$15.2M | -$14.5M | -$12.8M | -$16.0M | -$16.0M | -$10.3M | -$9.0M | -$8.4M |
| EPS (diluted) | $-0.40 | $-0.39 | — | $-0.62 | $-0.62 | $-0.40 | $-0.39 | — |
| EPS (basic) | $-0.40 | $-0.39 | $-0.45 | $-0.62 | $-0.62 | $-0.40 | $-0.39 | $-3.55 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $250.4M | $261.3M | $276.6M | $190.8M | $182.9M | $198.3M | $212.8M | $216.0M |
| Total liabilities | $10.7M | $11.3M | $15.7M | $10.4M | $11.5M | $13.5M | $14.8M | $5.8M |
| Stockholders' equity | $239.7M | $250.0M | $261.0M | $180.5M | $171.4M | $184.8M | $198.1M | $210.2M |
| Total current assets | $242.6M | $253.0M | $267.9M | $184.9M | $176.8M | $192.1M | $206.4M | $215.1M |
| Total current liabilities | $6.5M | $6.7M | $9.7M | $6.4M | $7.2M | $8.9M | $10.0M | $5.8M |
| Cash & equivalents | $14.7M | $20.2M | $75.6M | $42.6M | $20.8M | $22.5M | $21.9M | $40.9M |
| Marketable securities (current) | $221.8M | $226.2M | $187.3M | $139.8M | $154.7M | $168.2M | $182.8M | $173.0M |
| Property, plant & equipment | $929.0K | $1.1M | $830.0K | $880.0K | $856.0K | $891.0K | $989.0K | $888.0K |
| Other non-current assets | $364.0K | $312.0K | $256.0K | $266.0K | $186.0K | $4.0K | $3.0K | $3.0K |
| Accounts payable | $505.0K | $1.5M | $1.0M | $786.0K | $2.0M | $3.6M | $1.8M | $1.4M |
| Accrued liabilities | $3.6M | $2.9M | $6.4M | $4.1M | $3.7M | $3.8M | $6.7M | $3.8M |
| Other non-current liabilities | — | — | — | — | — | — | $0 | $0 |
| Common stock & paid-in capital | — | — | — | — | — | — | — | — |
| Retained earnings | -$207.0M | -$191.8M | -$177.4M | -$162.2M | -$149.4M | -$133.4M | -$117.4M | -$102.8M |
| Accumulated other comprehensive income (loss) | -$573.0K | -$253.0K | $260.0K | $265.0K | $147.0K | $170.0K | $71.0K | $561.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.5M | -$16.3M | -$13.0M | -$12.2M | -$15.7M | -$14.4M | -$10.2M | -$6.2M |
| Investing cash flow | $4.9M | -$39.3M | -$47.5M | $14.9M | $13.9M | $14.9M | -$9.4M | -$30.2M |
| Financing cash flow | $1.2M | $129.0K | $93.5M | $19.1M | $91.0K | $24.0K | $642.0K | $13.0K |
| Free cash flow | -$11.5M | -$16.6M | -$13.1M | -$12.3M | -$15.7M | -$14.5M | -$10.4M | -$6.3M |
| Capital expenditures | $6.0K | $312.0K | $42.0K | $98.0K | $44.0K | $47.0K | $166.0K | $82.0K |
| Depreciation & amortization | $134.0K | $83.0K | $85.0K | $81.0K | $79.0K | $78.0K | $75.0K | $62.0K |
| Share-based compensation | $3.8M | $3.8M | $2.5M | $2.6M | $2.4M | $2.6M | $2.3M | $2.3M |
| Change in accounts payable | -$990.0K | $490.0K | $162.0K | -$1.2M | -$1.6M | $1.8M | $378.0K | $663.0K |
| Purchases of investments | $45.8M | $97.1M | $84.7M | $18.6M | $25.4M | $33.7M | $54.4M | $72.4M |
| Debt repaid | — | — | — | — | — | — | $0 | $0 |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | — | $0 | $50.0M |
| Operating income | -$68.1M | -$50.9M | $16.1M |
| Net income | -$60.0M | -$42.3M | $22.7M |
| EPS (diluted) | $-2.17 | $-2.18 | $0.08 |
| EPS (basic) | $-2.17 | $-2.18 | $1.36 |
| Operating margin | — | — | $32 |
| Net margin | — | — | $45 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 |
|---|---|---|---|---|
| Total assets | $276.6M | $212.8M | $130.4M | — |
| Total liabilities | $15.7M | $14.8M | $5.7M | — |
| Stockholders' equity | $261.0M | $198.1M | -$67.9M | -$93.2M |
| Total current assets | $267.9M | $206.4M | $127.7M | — |
| Total current liabilities | $9.7M | $10.0M | $5.5M | — |
| Cash & equivalents | $75.6M | $21.9M | $15.5M | — |
| Marketable securities (current) | $187.3M | $182.8M | $109.7M | — |
| Property, plant & equipment | $830.0K | $989.0K | $678.0K | — |
| Other non-current assets | $256.0K | $3.0K | $1.3M | — |
| Accounts payable | $1.0M | $1.8M | $635.0K | — |
| Accrued liabilities | $6.4M | $6.7M | $4.4M | — |
| Other non-current liabilities | — | $0 | $110.0K | — |
| Retained earnings | -$177.4M | -$117.4M | -$75.1M | — |
| Accumulated other comprehensive income (loss) | $260.0K | $71.0K | $108.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Operating cash flow | -$55.3M | -$32.8M | $19.3M |
| Investing cash flow | -$3.7M | -$69.7M | -$65.6M |
| Financing cash flow | $112.7M | $109.0M | $56.2M |
| Free cash flow | -$55.5M | -$33.4M | $18.9M |
| Capital expenditures | $231.0K | $514.0K | $414.0K |
| Depreciation & amortization | $323.0K | $258.0K | $195.0K |
| Share-based compensation | $10.0M | $6.8M | $2.2M |
| Change in accounts payable | -$869.0K | $1.1M | $0 |
| Purchases of investments | $162.5M | $226.4M | $141.9M |
| Debt repaid | — | $0 | $3.8M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CTNM as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 30 filers
Held by These Filers72.4%
Shares Outstanding37,613,409
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| MONTANOVA CAPITAL, LLC | 2,841,334 | $46.6M | 7.55% | +0.0% | 2026-08-14 |
| Jupiter Topco LLC | 2,734,836 | $44.8M | 7.27% | +0.0% | 2026-08-14 |
| BlackRock, Inc. | 2,064,345 | $33.8M | 5.49% | +208.5% | 2026-08-07 |
| Johnson & Johnson | 1,979,173 | $32.4M | 5.26% | +0.0% | 2026-08-06 |
| Franklin Templeton Inc | 1,839,227 | $30.1M | 4.89% | +0.0% | 2026-08-04 |
| BALYASNY ASSET MANAGEMENT L.P. | 1,522,793 | $25.0M | 4.05% | -9.7% | 2026-08-13 |
| VANGUARD CAPITAL MANAGEMENT LLC | 1,321,356 | $21.7M | 3.51% | +8.8% | 2026-06-30 |
| PERCEPTIVE ADVISORS LLC | 1,255,592 | $20.6M | 3.34% | +0.0% | 2026-08-14 |
| FMR LLC | 1,040,130 | $17.0M | 2.77% | +27.6% | 2026-08-13 |
| MILLENNIUM MANAGEMENT LLC | 931,709 | $15.3M | 2.48% | -39.3% | 2026-08-14 |
| GREAT POINT PARTNERS LLC | 921,481 | $15.1M | 2.45% | +15.2% | 2026-08-14 |
| Longaeva Partners L.P. | 812,757 | $13.3M | 2.16% | +11.0% | 2026-08-13 |
| Ikarian Capital, LLC | 807,874 | $13.2M | 2.15% | +0.0% | 2026-08-14 |
| SECTORAL ASSET MANAGEMENT INC | 727,587 | $11.9M | 1.93% | +0.0% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 693,188 | $11.4M | 1.84% | +145.8% | 2026-08-12 |
| HHLR ADVISORS, LTD. | 669,337 | $11.0M | 1.78% | +0.0% | 2026-08-14 |
| Red Tree Management, LLC | 638,158 | $10.5M | 1.70% | +0.0% | 2026-07-22 |
| Versant Venture Management, LLC | 542,628 | $8.9M | 1.44% | +0.0% | 2026-08-12 |
| Goldman Sachs Group Inc | 497,255 | $8.2M | 1.32% | +61.9% | 2026-08-14 |
| Boxer Capital Management, LLC | 494,000 | $8.1M | 1.31% | +0.0% | 2026-08-14 |
| State Street Corp | 425,902 | $7.0M | 1.13% | +320.5% | 2026-08-07 |
| CITADEL ADVISORS LLC | 396,354 | $6.5M | 1.05% | +13.2% | 2026-08-14 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 328,000 | $5.4M | 0.87% | +0.0% | 2026-08-14 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 296,135 | $4.9M | 0.79% | -1.9% | 2026-08-07 |
| ADAR1 Capital Management, LLC | 278,961 | $4.6M | 0.74% | +0.8% | 2026-08-14 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Insider activity is not available for this symbol right now.
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 19:48 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-14 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-09-08 | 4 | 2026-09-08 | View on SEC.gov → |
| 2026-08-03 | 4 | 2026-08-03 | View on SEC.gov → |
| 2026-07-30 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-07-30 | 8-K | 2026-07-30 | View on SEC.gov → |
| 2026-07-13 | 8-K | 2026-07-13 | View on SEC.gov → |
| 2026-07-10 | 4 | 2026-07-08 | View on SEC.gov → |
| 2026-07-08 | 4 | 2026-07-08 | View on SEC.gov → |
| 2026-07-02 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-30 | View on SEC.gov → |
| 2026-06-26 | 4 | 2026-06-26 | View on SEC.gov → |
Recent news
Headlines about CTNM (Contineum Therapeutics, Inc. Class A). Links open the publisher — we don’t host full articles.
-
CTNM261218C00015000 Interactive Stock Chart | CTNM Dec 2026 15.000 call Stock
Yahoo Finance · 2026-10-21 -
CTNM Nov 2026 22.500 call (CTNM261120C00022500) stock price, news, quote and history
Yahoo Finance UK · 2026-10-17 -
(CTNM) Volatility Zones as Tactical Triggers
Stock Traders Daily · 2026-10-17 -
CTNM Dec 2026 20.000 call (CTNM261218C00020000) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-15 -
Jones Trading Maintains Buy on Contineum Therapeutics, Raises Price Target to $30
Benzinga · 2026-10-15 -
This Chemours Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Benzinga · 2026-10-14 -
Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14
Benzinga · 2026-10-14 -
Johnson & Johnson: Keep Calm And Hold On
SeekingAlpha · 2026-10-13
No headlines in this category right now — try “All”.